



B

Treatment scenario pattern	ITT analysis (% [n/N, 95% CI])	PP analysis (% [n/N, 95% CI])
TATT-ACE	68.52% (74/108, 59.62%-77.42%)	76.29% (74/97, 67.67%-84.91%)
TRBQT-ACEC	63.64% (28/44, 48.84%-78.43%)	73.68% (28/38, 59.02%-88.35%)
TRBQT-ACEB	66.25% (53/80, 55.66%-76.84%)	69.74% (53/76, 59.17%-80.3%)
TABQT-ACEC	85.71% (30/35, 73.52%-97.91%)	93.75% (30/32, 84.88%-100%)
TABQT-ACEB	88.46% (69/78, 81.21%-95.71%)	93.24% (69/74, 87.39%-99.1%)

Supplement Fig. S1 The comparison of eradication rate in patients with Clarithromycin susceptibility by two treatments.

ITT=intention-to-treat analysis. PP=per-protocol analysis. TABQT=Tailored Bismuth-containing quadruple therapy. TATT=Tailored triple therapy.

TRBQT=Tranditonal Bismuth-containing quadruple therapy. ACE= amoxicillin+clarithromycin+esomeprazole. ACEC=

amoxicillin+clarithromycin+esomeprazole+colloidal bismuth subcitrate. ACEB= amoxicillin+clarithromycin+esomeprazole+bismuth potassium citrate.

Different letters above the columns indicate significant differences ($P < 0.05$).